{"nctId":"NCT01068678","briefTitle":"Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2010-02"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":460,"armGroups":[{"label":"IDeg 3 times weekly (3TW)","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec"]},{"label":"IGlar OD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin glargine"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"insulin glargine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Insulin na√Øve subject (allowed are: previous short term insulin treatment up to 14 days; Treatment during hospitalisation or during gestational diabetes is allowed for periods longer than 14 days)\n* Current treatment: metformin monotherapy or metformin in any combination with insulin secretagogues (sulphonylurea (SU) or glinide), DPP-4 inhibitor, alpha-glucosidase-inhibitor (acarbose) with unchanged dosing for at least three months prior to Visit 1 with the minimum doses stated: -Metformin: alone or in combination (including fixed combination) 1500 mg daily or maximum tolerated dose (at least 1000 mg daily) -Insulin secretaguogue (sulfonylurea or glinide): minimum half of the daily maximal dose according to local labelling -DPP-4 inhibitor: minimum half of the daily maximal dose according to local labelling -alpha-glucosidase-inhibitor (acarbose): minimum half of the daily maximal dose or maximum tolerated dose\n* HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis\n* Body Mass Index (BMI) below or equal to 45.0 kg/m\\^2\n\nExclusion Criteria:\n\n* Use within the last 3 months prior to Visit 1 of: thiazoledinediones, exenatide or liraglutide\n* Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty\n* Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)\n* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements (for UK: adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, sterilisation, intrauterine device or intrauterine system, or consistent use of barrier methods)\n* Cancer and medical history of cancer hereof (except basal cell skin cancer or squamous cell skin cancer)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycosylated Haemoglobin (HbA1c)","description":"Change from baseline in HbA1c after week 26","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":"0.95"},{"groupId":"OG001","value":"-1.40","spread":"1.07"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change from baseline in body weight after week 26","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"3.6"},{"groupId":"OG001","value":"1.0","spread":"3.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":227},"commonTop":["Headache","Diarrhoea","Nasopharyngitis","Back pain","Nausea"]}}}